125 related articles for article (PubMed ID: 23528258)
1. Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication.
Debing Y; Kaplan GG; Neyts J; Jochmans D
Antiviral Res; 2013 May; 98(2):325-31. PubMed ID: 23528258
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells.
Jiang X; Kanda T; Nakamoto S; Saito K; Nakamura M; Wu S; Haga Y; Sasaki R; Sakamoto N; Shirasawa H; Okamoto H; Yokosuka O
Biochem Biophys Res Commun; 2015 Mar; 458(4):908-12. PubMed ID: 25704089
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.
Yang L; Kiyohara T; Kanda T; Imazeki F; Fujiwara K; Gauss-Müller V; Ishii K; Wakita T; Yokosuka O
Virol J; 2010 Sep; 7():212. PubMed ID: 20815893
[TBL] [Abstract][Full Text] [Related]
4. The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity.
Kanda T; Sasaki R; Nakamoto S; Haga Y; Nakamura M; Shirasawa H; Okamoto H; Yokosuka O
Biochem Biophys Res Commun; 2015 Oct; 466(3):567-71. PubMed ID: 26388050
[TBL] [Abstract][Full Text] [Related]
5. Amantadine and Rimantadine Inhibit Hepatitis A Virus Replication through the Induction of Autophagy.
Sasaki-Tanaka R; Shibata T; Moriyama M; Okamoto H; Kogure H; Kanda T
J Virol; 2022 Sep; 96(18):e0064622. PubMed ID: 36040176
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system.
Jiang W; Muhammad F; Ma P; Liu X; Long G
Antiviral Res; 2018 Jun; 154():51-57. PubMed ID: 29653132
[TBL] [Abstract][Full Text] [Related]
7. Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.
Esser-Nobis K; Harak C; Schult P; Kusov Y; Lohmann V
Hepatology; 2015 Aug; 62(2):397-408. PubMed ID: 25866017
[TBL] [Abstract][Full Text] [Related]
8. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis.
Li Y; Misumi I; Shiota T; Sun L; Lenarcic EM; Kim H; Shirasaki T; Hertel-Wulff A; Tibbs T; Mitchell JE; McKnight KL; Cameron CE; Moorman NJ; McGivern DR; Cullen JM; Whitmire JK; Lemon SM
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2204511119. PubMed ID: 35867748
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA.
Brack K; Berk I; Magulski T; Lederer J; Dotzauer A; Vallbracht A
J Virol; 2002 Dec; 76(23):11920-30. PubMed ID: 12414934
[TBL] [Abstract][Full Text] [Related]
10. Drug Screening for Hepatitis A Virus (HAV): Nicotinamide Inhibits c-Jun Expression and HAV Replication.
Sasaki-Tanaka R; Masuzaki R; Okamoto H; Shibata T; Moriyama M; Kogure H; Kanda T
J Virol; 2023 Feb; 97(2):e0198722. PubMed ID: 36728416
[TBL] [Abstract][Full Text] [Related]
11. Molecular biology and inhibitors of hepatitis A virus.
Debing Y; Neyts J; Thibaut HJ
Med Res Rev; 2014 Sep; 34(5):895-917. PubMed ID: 23722879
[TBL] [Abstract][Full Text] [Related]
12. Cell Culture Systems and Drug Targets for Hepatitis A Virus Infection.
Kanda T; Sasaki R; Masuzaki R; Matsumoto N; Ogawa M; Moriyama M
Viruses; 2020 May; 12(5):. PubMed ID: 32408660
[TBL] [Abstract][Full Text] [Related]
13. Anti-HAV activity of some newly synthesized triazolo[4,3-b]pyridazines.
Shamroukh AH; Ali MA
Arch Pharm (Weinheim); 2008 Apr; 341(4):223-30. PubMed ID: 18214848
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation.
Kanda T; Wu S; Kiyohara T; Nakamoto S; Jiang X; Miyamura T; Imazeki F; Ishii K; Wakita T; Yokosuka O
Viral Immunol; 2012 Oct; 25(5):379-86. PubMed ID: 23035851
[TBL] [Abstract][Full Text] [Related]
15. Interference of hepatitis A virus replication by small interfering RNAs.
Kanda T; Kusov Y; Yokosuka O; Gauss-Müller V
Biochem Biophys Res Commun; 2004 May; 318(2):341-5. PubMed ID: 15120607
[TBL] [Abstract][Full Text] [Related]
16. Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site.
Kanda T; Zhang B; Kusov Y; Yokosuka O; Gauss-Müller V
Biochem Biophys Res Commun; 2005 May; 330(4):1217-23. PubMed ID: 15823573
[TBL] [Abstract][Full Text] [Related]
17. Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression.
Nwe Win N; Kanda T; Nakamura M; Nakamoto S; Okamoto H; Yokosuka O; Shirasawa H
Biochem Biophys Res Commun; 2017 Jan; 483(1):694-699. PubMed ID: 27986562
[TBL] [Abstract][Full Text] [Related]
18. Methisoprinol-effect on the replication cycle of human hepatitis A virus.
Divizia M; Venuti A; Degener AM; Perez-Bercoff R; Panà A
Microbiologica; 1992 Oct; 15(4):323-8. PubMed ID: 1279362
[TBL] [Abstract][Full Text] [Related]
19. In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks.
Osiceanu AM; Murao LE; Kollanur D; Swinnen J; De Vleeschauwer AR; Lefebvre DJ; De Clercq K; Neyts J; Goris N
Antiviral Res; 2014 May; 105():59-63. PubMed ID: 24583031
[TBL] [Abstract][Full Text] [Related]
20. HAV replication in acute hepatitis with typical and atypical clinical course.
Sagnelli E; Coppola N; Marrocco C; Onofrio M; Scarano F; Marotta A; Scolastico C; Catuogno A; Salzillo A; Sagnelli C; Piccinino F; Filippini P
J Med Virol; 2003 Sep; 71(1):1-6. PubMed ID: 12858402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
